Effect of FK506 in reducing scar formation by inducing fibroblast apoptosis after sciatic nerve injury in rats

J Que¹,², Q Cao¹,³, T Sui², S Du², D Kong² and X Cao*¹,²

We previously demonstrated that FK506, a generally applied immunosuppressant in organ transplantation, could promote peripheral nerve regeneration through reducing scar formation. However, little is known about how FK506 reduces scar formation. Herein we investigated the influence of FK506 on fibroblast proliferation and its correlation with scar formation after sciatic nerve injury in rats, and further explored the effect of FK506 on fibroblast proliferation and apoptosis in vitro. Masson staining and immunohistochemistry revealed that scar area and fibroblast number in the nerve anastomosis of sciatic nerve-injured rats were significantly reduced after FK506 administration. The scar area had a significant positive correlation with the fibroblast number, as detected by linear correlation analysis. CCK-8 assay and flow cytometry indicated that FK506 also inhibited proliferation and induced apoptosis of fibroblasts in vitro. It was primarily phosphorylation of JNK and ERK that were activated during the apoptosis of fibroblast. Pretreatment of cells with JNK inhibitor, SP600125, or ERK inhibitor, PD98059, could inhibit FK506-induced fibroblast apoptosis, respectively. Moreover, simultaneous application of both inhibitors had additive roles in cell protection from apoptosis. These results suggest that FK506-induced fibroblast apoptosis contributes to the suppression of fibroblast proliferation and then results in the reduction of scar formation in sciatic nerve-injured rat, and that JNK and ERK are involved in FK506-induced fibroblast apoptosis.

Received 08.8.12; revised 30.1.13; accepted 04.2.13; Edited by E Candi

Results

Effect of FK506 on scar formation and fibroblast proliferation in histological analysis. At 4 weeks after establishing the nerve injury model, Masson staining showed extensive collagen tissue hyperplasia in nerve anastomosis of the model group (Figure 1A), as seen by the blue staining. Immunohistochemistry showed that a large amount of fibroblasts mixed with fibrocytes appeared in the model group (Figure 1a). In the FK506 group (Figures 1B and b), collagen tissue hyperplasia and fibroblasts mixed with fibrocytes obviously decreased in nerve anastomosis compared with those of the model group. Meanwhile, collagen tissue and fibroblasts were rarely visible in nerve anastomosis of the normal control group (Figures 1C and c).

Effect of FK506 on fibroblast number in sciatic nerve anastomosis of rats and its correlation with scar area. As shown in Figure 2a, the scar area of nerve anastomosis was significantly increased in the model group (4.36 ± 0.68 mm²) compared with the normal control group (0.37 ± 0.14 mm², P < 0.01), and significantly decreased in the FK506 group (1.61 ± 0.42 mm²) compared with the model group (P < 0.05). As shown in Figure 2b, the fibroblast proliferation...
The number of nerve anastomosis was significantly increased in the model group (37.3 ± 4.85) compared with the normal control group (3.8 ± 1.03, \( P < 0.01 \)), and significantly decreased in the FK506 group (16.5 ± 3.24) compared with the model group (\( P < 0.05 \)). Linear correlation analysis results showed that the scar area of nerve anastomosis augmented with increased fibroblast number. Thus, the scar area had a significant positive correlation with the fibroblast number (\( r = 0.9915, \ P < 0.0001 \)), suggesting that FK506 reduces scar formation by inhibiting fibroblast proliferation (Figure 2c).

FK506 induced significant apoptosis of fibroblast. As the CCK-8 assay demonstrated that FK506 could inhibit the proliferation of fibroblast in a dose-dependent manner, flow cytometry was further used to identify the types of cell death. As shown in Figure 4, fibroblasts showed a dose-dependent apoptosis, including early as well as late apoptotic cell death. The mean percentage of apoptotic cell death was about (14.7 ± 6.89), (45.7 ± 7.05) and (86.8 ± 6.83)% in cells treated with 12.5, 25 and 50 \( \mu \)M FK506, respectively. In contrast, the cells that had not been treated with FK506 demonstrated normal cell viability without abnormal cell death.

Morphological changes by fluorescence microscopy. In order to characterize the pattern of apoptotic status mediated by FK506 in fibroblasts, morphological examinations were performed. As shown in Figure 5, normal fibroblasts exhibited intact nuclei and adqulis chromatin. In comparison, after FK506 treatment and fluorescence microscopy using Hoechst 33342 staining, shrunken cells with condensed or fragmented nuclei were observed. In cells treated with 50 \( \mu \)M FK506, the fibroblasts exhibited condensed and fragmented nuclei.
FK506, significant chromatin agglutination and nuclear fragmentation, both characteristic of apoptosis, were observed.

FK506 activated JNK and ERK, and enhanced expressions of cytosolic cytochrome c and cleaved caspase-3. JNK, ERK, cytochrome c and cleaved caspase-3 are all known to be involved in the regulation of apoptosis. Their expression levels after FK506 treatment for 8 h were detected by western blotting. As shown in Figure 6, the levels of GAPDH expression were comparable among the negative control group, the dimethyl sulfoxide (DMSO) group and the three FK506 treatment groups. In contrast, phosphorylation of JNK (p-JNK) could not be activated in either the negative control group or the DMSO group. Increasing expression of p-JNK was observed in fibroblasts after FK506 treatment at increasing concentrations; this expression peaked at the concentration of 50 µM. This suggests that JNK can be activated by FK506. The kinetics and the extent of phosphorylation of ERK (p-ERK), cytosolic cytochrome c and cleaved caspase-3 had a similar pattern of increase.

**Figure 3** Effect of FK506 on fibroblast proliferation in vitro. Rat skin fibroblasts were treated with increasing concentrations of FK506 for 8 h. The viable cells were measured by CCK-8 assay. FK506 inhibited fibroblast proliferation in a dose-dependent manner. Cell viability reached a relatively minimal level at 75 µM. *P < 0.05, **P < 0.01 compared with control. All experiments were performed three times with comparable results.

**Figure 4** FK506 induced significant apoptosis of fibroblasts. Cells were incubated either in the absence of (control) or in the presence of FK506 (12.5, 25 and 50 µM) for 8 h. Fibroblasts showed a dose-dependent apoptosis through the detection of flow cytometry. The mean percentage of apoptotic cell death was about (14.7 ± 6.89), (45.7 ± 7.05) and (86.8 ± 6.83)% in cells treated with 12.5, 25 and 50 µM FK506, respectively. *P < 0.05, **P < 0.01 compared with control.

**Figure 5** Morphological features of fibroblast apoptosis induced by FK506. Cells were treated with increasing concentrations of FK506 for 8 h. Following Hoechst 33342 staining, the morphological features of apoptosis were observed by fluorescence microscopy. Normal fibroblasts exhibited intact nuclei and asperly chromatin. Shrunken cells with condensed or fragmented nuclei were observed after FK506 treatment. Arrows showing condensed or fragmented nuclei. Images × 400 magnified, scale bar 5.5 µm.
resulting from FK506 treatment. The highest expressions of p-ERK, cytosolic cytochrome c and cleaved-caspase-3 was reached at the FK506 concentration of 50 μM. FK506 also activated ERK, and enhanced expression of cytosolic cytochrome c and cleaved caspase-3.

**JNK inhibitor, SP600125, or/and ERK inhibitor, PD98059, reduced FK506-induced apoptosis of fibroblasts.** The effects of JNK inhibitor, SP600125, and ERK inhibitor, PD98059, were investigated to demonstrate the role of JNK and ERK in FK506-induced apoptosis. As shown in Figure 7, preincubation with SP600125 or PD98059 for 30 min before 50 μM FK506 treatment significantly reduced the apoptotic rate. The mean percentage of apoptotic cell death decreased to (61.1 ± 7.18) and (67.6 ± 7.59)% in cells pretreated with SP600125 and PD98059, respectively, compared with that of cells treated with 50 μM FK506 alone (87.9 ± 6.69)% (P<0.05). In addition, preincubation with the two inhibitors together further decreased the apoptotic percentage to (39.87 ± 4.57)%, compared with SP600125 or PD98059 pretreatment, respectively (P<0.05).

**JNK inhibitor, SP600125, or/and ERK inhibitor, PD98059, weakened expressions of p-JNK or p-ERK and cleaved caspase-3.** As shown in Figure 8, SP600125 prevented both the phosphorylation of JNK and the expressions of cytosolic cytochrome c and cleaved-caspase-3. However, PD98059 only prevented the phosphorylation of ERK and the expression of cleaved caspase-3, and had no effect on the expression of cytosolic cytochrome c. Moreover, simultaneous application of both inhibitors further decreased the expression of cleaved caspase-3 (P<0.05), and almost had no influence on the expressions of p-JNK, p-ERK and cytosolic cytochrome c, compared with SP600125 or PD98059 pretreatment, respectively.

**Discussion**

Following traumatic peripheral nerve injury, fibroblasts were activated by inflammatory cytokines and growth factors, such as transforming growth factor-β (TGF-β) and basic fibroblast growth factor. Proliferative fibroblasts produce a great amount of collagen fibers that contribute to scar formation at the nerve anastomotic sites, and preventing fibroblast proliferation can reduce scar area.20,21 In this study, multiple parameters including the histological analysis, the area of scar tissue and the number of fibroblasts were used to evaluate the effect of FK506 on fibroblast proliferation and scar formation in rats' model after sciatic nerve injury. Furthermore, we performed successive transversal sections through the anastomotic sites to make the scar area analysis and fibroblast counting in histological evaluation. Therefore, the mean values could reflect the amount of scar area and fibroblast number, and it was a valid method to the quantitative evaluation of fibroblast proliferation and scar formation.

With FK506 gavage (4 mg/kg per day) for 4 weeks after sciatic nerve injury, the scar area and fibroblast number were significantly decreased in the FK506 group compared with the model group. These results showed that FK506 could inhibit fibroblast proliferation and reduce scar formation at the nerve anastomotic sites. Moreover, correlation analysis indicated that the scar area was positively correlated with the fibroblast number, which further confirmed that FK506 can reduce scar formation in some way by inhibiting fibroblast proliferation after sciatic nerve injury in rats.

The study further investigated the influence of FK506 on fibroblast proliferation *in vitro*. The CCK-8 assay demonstrated that FK506 could inhibit the proliferation of cultured rat skin fibroblasts in a dose-dependent manner. Then the effect of FK506 on fibroblast apoptosis *in vitro* was examined. Hoechst 33342 staining showed that the fibroblasts subjected to FK506 exhibited condensed or fragmented nuclei. Furthermore, flow cytometric analysis showed a significant increase, in a dose-dependent manner, in the percentage of apoptotic cells. The more the apoptotic cells, the less the cells available for proliferation. Thus, these results suggest that FK506-induced fibroblast apoptosis contributes to the suppression of fibroblast proliferation and then results in the reduction of scar formation in sciatic nerve-injured rat.

Furthermore, we explored the cell signaling that may be involved in FK506-induced fibroblast apoptosis. We found that fibroblast apoptosis induced by FK506 could be inhibited by...
JNK inhibitor, SP600125, or/and ERK inhibitor, PD98059, reduced FK506-induced apoptosis of fibroblasts. Cells were preincubated with JNK inhibitor, SP600125 (40 \mu M), or/and ERK inhibitor, PD98059 (60 \mu M), for 30 min before treatment with 50 \mu M FK506 for 8 h. The apoptosis rate was detected by flow cytometry. The mean percentage of apoptotic cell death decreased to (61.1 \pm 7.18) and (67.6 \pm 7.59)\% in cells pretreated with SP600125 and PD98059, respectively, compared with that of cells treated with 50 \mu M FK506 alone (87.9 \pm 6.69)\%. Preincubation with the two inhibitors together further decreased the apoptotic percentage to (39.87 \pm 4.57)\%, compared with SP600125 or PD98059 pretreatment, respectively. *P<0.05, **P<0.01, compared with control. #P<0.05 compared with cells treated with 50 \mu M FK506 alone. *P<0.05 compared with SP600125 or PD98059 pretreatment, respectively.

![Figure 7](image)

**Figure 7** JNK inhibitor, SP600125, or/and ERK inhibitor, PD98059, reduced FK506-induced apoptosis of fibroblasts. Cells were preincubated with JNK inhibitor, SP600125 (40 \mu M), or/and ERK inhibitor, PD98059 (60 \mu M), for 30 min before treatment with 50 \mu M FK506 for 8 h. The apoptosis rate was detected by flow cytometry. The mean percentage of apoptotic cell death decreased to (61.1 \pm 7.18) and (67.6 \pm 7.59)\% in cells pretreated with SP600125 and PD98059, respectively, compared with that of cells treated with 50 \mu M FK506 alone (87.9 \pm 6.69)\%. Preincubation with the two inhibitors together further decreased the apoptotic percentage to (39.87 \pm 4.57)\%, compared with SP600125 or PD98059 pretreatment, respectively. *P<0.05, **P<0.01, compared with control. #P<0.05 compared with cells treated with 50 \mu M FK506 alone. *P<0.05 compared with SP600125 or PD98059 pretreatment, respectively.

JNK inhibitor, SP600125, or/and by ERK inhibitor, PD98059. JNK and ERK are members of the mitogen-activated protein kinase (MAPK) family. JNK can be rapidly activated by various stress stimuli and mostly mediates apoptosis, whereas the ERK cascade is activated by mitogenic stimuli, and is critical for proliferation and survival. However, JNK and ERK are controversial in their role in cell death or proliferation. JNK has been reported to induce pro-survival responses in several types of cells and ERK also has been suggested to mediate apoptosis. What determines whether JNK and ERK will act in a pro-apoptotic or pro-survival fashion remains an important unanswered question, but the different stimuli as
well as the cell type may be determining factors. The role of MAPKs on apoptotic pathways may be unique to the specific model tested, and to the apoptotic trigger assessed.\textsuperscript{32} This study found that FK506 induced sustained activation (phosphorylation) of JNK and ERK in fibroblasts in a dose-dependent manner. JNK mostly mediates apoptosis, whereas the accumulation of p-ERK in the cytoplasm raises the possibility that kinase may not be available to act on potential downstream pro-survival targets and may contribute to apoptosis through the activation of cytoplasmic cell death mediators.\textsuperscript{33} SP600125 or PD98059 effectively blocked FK506-induced JNK or ERK activation and attenuated FK506-induced apoptosis, suggesting that the sustained activation of JNK and ERK signaling pathways may be involved in FK506-induced fibroblast apoptosis.

Western blot analysis of cytosolic cytochrome c protein was performed to examine whether FK506 induced fibroblast apoptosis involving the mitochondria. Mitochondria act as an important apparatus for signals during apoptosis, and the loss of mitochondrial membrane integrity can induce the release of cytochrome c from mitochondria into cytosol.\textsuperscript{34} The release of cytochrome c is important in this apoptotic pathway, as cytochrome c binds to apoptotic protease-activating factor-1 (Apaf-1) forming a complex that in turn cleaves caspase-3.\textsuperscript{35} In this study, the level of cytosolic cytochrome c significantly increased in a dose-dependent manner after FK506 treatment. After preincubation with JNK inhibitor SP600125, the p-JNK and cytosolic cytochrome c were markedly decreased. Preincubation with ERK inhibitor PD98059, however, resulted in a significant decrease of p-ERK, leaving the level of cytosolic cytochrome c almost unchanged. These results indicated that mitochondria have a critical role and that p-JNK, but not p-ERK, is involved in mitochondrial pathway of FK506-induced fibroblast apoptosis.

Caspase-3 is one of the key agents of apoptosis, as it is either partially or totally responsible for the proteolytic cleavage of many key proteins.\textsuperscript{36} Although p-ERK had no effect on the release of cytochrome c, it still contributed to the activation of caspase-3. Preincubation with SP600125 or PD98059 both led to a significant decrease of cleaved caspase-3. Moreover, simultaneous application of the two inhibitors had additive roles that further decreased the expression of cleaved caspase-3 and the apoptotic percentage, and almost had no influence on the expressions of p-JNK, p-ERK and cytosolic cytochrome c, compared with SP600125 or PD98059 pretreatment, respectively. These observations further demonstrated that JNK and ERK pathways are independently involved, but have additive roles in FK506-induced fibroblast apoptosis.

In conclusion, FK506 activates both JNK and ERK with or without mitochondrial cytochrome c release, followed by the cleavage of caspase-3, subsequently leading to the apoptosis of fibroblasts, and FK506 has a valid effect on reducing scar formation in sciatic nerve-injured rat by inducing fibroblast apoptosis. Further research is needed to study at the effect of FK506 on other extracellular matrix components in the process of scar formation. Experiments will be continuously performed in vitro to further elucidate the signaling pathways of FK506-induced apoptosis in fibroblasts.

Materials and methods

Animals and establishment of rat sciatic nerve transaction anastomosis models. Healthy male Sprague–Dawley rats, weighing 250–300 g were purchased from Shanghai Laboratory Animal Center, the Chinese Academy of Sciences (Shanghai, China). All procedures were approved by the Animal Ethics Committee of Nanjing Medical University in China and were in compliance with the Guide for the Care and Use of Laboratory Animals published by the Chinese National Institute of Health. Rats were anesthetized by 30 mg/kg sodium pentobarbital via intraperitoneal injection and fixed in an abduction position at room temperature. After the right thigh and buttock were shaved, a longitudinal incision was made along the median femur to expose ~2 cm of the sciatic nerve. The greater sciatic foramen was cut at the tendon level of the obturator internus muscle. The incision was sutured with three sutures under ×10 magnification using a surgical microscope (Latic Instrument Factory, Shanghai, China) and 10/0 nylon monofilament (Latic Suture Needle Company Ltd., Ningbo, China). Rats were postoperatively injected with penicillin 1 600 000 U/kg at the non-operated side to prevent infection.

Drug intervention in vivo. FK506 was purchased from Sigma (St. Louis, MO, USA), containing 1 mg per capsule. After the capsule dressing was removed, the powder was dissolved in saline and prepared into a homogeneous suspension with a final concentration of 0.5 mg/ml by microwaving for 5 min. Rats were intragastically injected with the suspension at a dose of 4 mg/kg per day after model establishment. Thirty rats were randomly divided into three groups (ten rats in each group): model group, saline gavage for 4 weeks after sciatic nerve injury; FK506 group, FK506 gavage for 4 weeks after sciatic nerve injury; normal control group, saline gavage for 4 weeks without sciatic nerve injury.

Harvesting the sciatic nerve. At 4 weeks after model establishment, all the rats of each group were sacrificed. The operative sciatic nerve was completely dissected, a 5-mm-long nerve trunk was cut from 2.5 mm lateral to the distal and proximal ends of the anastomosis, followed by labeling, conventional fixation, dehydration, transparency, permeation, embedding, coating, paraffin mounting and sliding into 4-μm thick transversal sections. Twelve successive transversal sections of each rat were made through the anastomosis from the proximal to the distal end.

Masson staining. Six odd sections of each rat were stained with Masson’s trichrome. Sections were dewaxed and mordanted (10% potassium dichromate + 10% trichloroacetic acid) for 30 min, nuclei were stained with hematoxylin for 20 min, differentiated with hydrochloric acid and ethanol for 15 s, returned to blue with weak ammonia for 15 s, stained with Masson solution (Cell Signaling Technology, Irvine, CA, USA) for 1 min, rinsed with 1% acetic acid, dehydrated with an increasing ethanol series, cleared with xylene I and II for 10 min to make sections transparent and finally sealed in resin. Then collagen fiber proliferation was observed under the light microscope (Olympus, Tokyo, Japan) with the magnification of ×400.

Immunohistochemical analysis. Six even sections of each rat were dewaxed and rehydrated through gradient ethanol solutions. The sections were incubated in citrate buffer to activate the antigenicity and exposed to 3% H₂O₂ for 10 min to block endogenous peroxidase. All subsequent incubations were performed in a humidified chamber at 37 °C unless otherwise stated. The sections were blocked in common goat serum solution for 15 min, followed by incubation overnight with rabbit polyclonal anti-TGF-β/I (1:50) at 4 °C. Sections were then washed in phosphate buffered saline (PBS) and incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG antibody for 15 min. The cells were visualized by using 3,3′-diaminobenzidine for 5 min at room temperature, and the sections were counterstained with hematoxylin for 2 min. The sections were analyzed under light microscope with the magnification of ×400.

Histological image analysis. Six sections of each rat stained with Masson’s trichrome were selected and the histological images at ×12.5 magnification were obtained. The areas of scar tissue were automatically calculated by Image-pro plus 5.0 image analysis software (Media Cybernetics, Shanghai, China). The area of scar tissue for each rat was defined as the mean scar area of six sections and expressed in mm². Another six sections stained with TGF-β/I antibody of each rat were selected, and the histological images at ×400 magnification were also obtained. The counting area was selected and each was about 100,000×100,000μm from three fields on each section. The number of...
fibroblast was calculated, and the number of fibroblast for each section was defined as the mean number of three fields, and the number for each rat was defined as the mean number of six sections.

**Culture of rat skin fibroblasts and drug intervention in vitro.** Primary cultures of rat skin fibroblasts were obtained from male Sprague–Dawley newborn rats (Shanghai Laboratory Animal Center, the Chinese Academy of Sciences) 1–2 days after birth as reported previously, with minor modifications. In brief, after thiopental anesthesia, the skin of dorsal part of the lumbar region was shaved and disinfected with 70% ethanol. Skin samples were aseptically removed from the rats and then minced and incubated for 3 h in 0.1% collagenase solution (37 °C, 5% CO₂). After incubation, the cell suspension was centrifuged at 250 × g for 5 min. The supernatant was discarded, and the isolated cells were cultured in DMEM (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS, USA), 100 U/ml penicillin G and 100 U/ml streptomycin. After 2 h, the nonadherent cells were washed out. Cells were cultured in an atmosphere of 5% CO₂ at 37°C. After confluence was attained, cells were subcultivated by a 5-min incubation in 0.1% trypsin and 5 mM ethylenediaminetetraacetic acid (EDTA). The free cells were added to an equal volume of culture medium. Following centrifugation (12,000 g for 5 min), cells were resuspended in culture medium. The thin and triangular cells with light cytoplast present in the culture were identified as fibroblasts. The purity of the cultures and absence of other cells were confirmed by morphological examinations. Supplied as a crystalline solid containing 5 mg per bottle, FK506 was dissolved in DMSO and stored at −20°C. The serum-free medium containing different concentrations of FK506 (12.5 μM, 25, 50, 75 and 100 μM) were freshly prepared for each experiment. Preincubation with JNK inhibitor, SP600125 (40 μM), oriand ERK inhibitor, PD98059 (60 μM), was carried out for 30 min before cells were treated with 50 μM FK506. FK506, DMSO, SP600125 and PD98059 were purchased from Sigma.

**CCK-8 assay.** Cells were plated in 96-well plates (100 μL, 5 × 10⁴ per well) and allowed to adhere for 24 h at 37°C. The cells were then treated with increasing concentrations of FK506 for 6 h. Following treatments, CCK-8 (Dojindo Laboratories, Kumamoto, Japan) solution (10 μl) was added to each well. After incubation at 37°C for another 2 h, viable cells were detected by measuring absorbance at 570 nm using an absorbance microplate reader (ELx800 Absorbance Microplate Reader, Bio-Tek, Seattle, WA, USA). Cell viability was expressed as the percentage absorbance of cells treated with FK506 compared with the percentage absorbance of untreated cells.

**Flow cytometry.** Fibroblasts were plated in 6-well plates (2 ml, 1 × 10⁵ per well) and incubated overnight at 37°C. After FK506 treatment, cells were harvested, washed twice with pre-chilled PBS, resuspended in 1 × binding buffer at 1 × 10⁶ cells/ml, and then incubated with Annexin V-FITC and Propidium Iodide (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The mixed solution was gently vortexed and incubated in the dark on ice for 15 min. The apoptosis rate of fibroblasts was detected by an FACSsia flow cytometer with FACSDiva Software (Becton Dickinson, San Jose, CA, USA) within 1 h.

**Hoechst 33342 staining.** Fibroblasts were plated in 6-well plates (2 ml, 1 × 10⁵ per well) and incubated to adhere overnight at 37°C. Increasing concentrations of FK506 were then added to each well and incubated for another 8 h at 37°C. The fibroblastic monolayer was then washed three times with PBS and stained with 5 μg/ml Hoechst 3342 for 30 min at 37°C in the dark. Following staining, fibroblasts were washed three times with PBS. The morphological features of apoptosis were observed by fluorescence microscopy (Olympus BX 51) with the magnification × 400.

**Western blotting.** Cells were harvested and washed three times with cold PBS. Then cells were lysed with lysis buffer (1% Nonidet P-40, 50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM EDTA, 10 μg/ml aprotinin, 10 μg/ml leupeptin and 1 mM PMSF). Lysates was centrifuged at 12,000 × g for 30 min at 4°C. The supernatant was collected and protein concentrations were determined using BCA assay kit (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions. Cellular extract containing 50 μg of total protein from each sample were separated by 12% SDS-PAGE and transferred to PVDF membranes using a standard protocol. The membranes were blocked with TBS-0.05% Tween-20 containing 5% (v/v) bovine serum albumin (Sigma) for 90 min at 37°C, then incubated with primary antibodies overnight at 4°C. The following antibodies were used: GAPDH, JNK, ERK, p-JNK, p-ERK (Cell Signaling Technology, 1:1000 dilution) and cleaved caspase-3 (Abcam, Cambridge, UK, 1:200 dilution). The second day, membranes were washed three times and hybridized with horseradish peroxidase-conjugated secondary antibody (Sigma, 1:10,000 dilution) for 2 h at 37°C. After washing three times, protein bands specific for antibody were visualized by fluorography using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Band densities were quantified using Image-J, a public domain Java Image-processing program inspired by NIH and were normalized to GAPDH to correct for variations in protein loading.

**Measurement of cytosolic cytochrome c.** Cells were resuspended in buffer (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 17 μg/ml of PMSF, 8 μg/ml of aprotinin and 2 μg/ml of leupeptin, pH 7.4) on ice for 30 min and then homogenized gently with a glass Dounce homogenizer for 20 strokes. The homogenates were centrifuged at 750 × g for 10 min at 4°C to remove nuclei, and the supernatants were centrifuged at 20,000 × g for 30 min at 4°C to remove mitochondria and other insoluble fragments. Protein (50 μg) was subjected to 12% SDS-PAGE, and then western blot analysis was performed using anticytochrome c antibody (Abcam, 1:500 dilution).

**Statistical analysis.** Data are presented as mean ± S.D. Statistical significance was determined using analysis of variance (ANOVA). A P-value of <0.05 was considered statistically significant. The correlation between scar area and fibroblast number was analyzed using linear correlation analysis, with P<0.05 indicating correlation.

**Conflict of Interest**

The authors declare no conflict of interest.

**Acknowledgements.** This study was supported by grants from the National Natural Science Foundation of China (No. 30973085, 81171694) and the Program for Development of Innovative Research Team in the First Affiliated Hospital of Nanjing Medical University (No. IRT-015). All authors participated in the study design, conduction, evaluation and all contributed to preparation of the manuscript. Jun Que and Quan Cao drafted the manuscript.

1. Sosa I, Reyes O, Kuffler DP. Immunosuppressants: neuroprotection and promoting neurological recovery following peripheral nerve and spinal cord lesions. Exp Neurol 2005; 195: 7–15.
2. Rustmeyer J, Dickie U. Allografting combined with systemic FK506 produces greater functional recovery than conduit implantation in a rat model of sciatic nerve injury. J Reconstr Microsurg 2010; 26: 123–129.
3. Graham WP, Pataly PE, Calabretta AM, Munger BL, Buda MJ. Enhancement of peripheral nerve regeneration with trimamolinone after neurotomy. Surg Forum 1973; 24: 457–459.
4. Lane JM, Bora FW, Plesser D. Neuroma scar formation in rats following peripheral nerve transection. J Bone Joint Surg Am 1978; 60: 197–203.
5. Sunderland S. Nerve and Nerve Injury. Churchill Livingstone: New York, 1987. pp 173–176.
6. Atkins S, Smith KG, Loescher AR, Boissonade FM, O’Kane S, Ferguson MW et al. Scarring impedes regeneration at sites of peripheral nerve repair. Neuroreport 2006; 17: 1245–1249.
7. Bora FJ. Peripheral nerve repair in cats. The fascicular stitch. J Bone Joint Surg 1967; 49: 659–666.
8. Yan Y, Sun HH, Hunter DA, Mackinnon SE, Johnson PJ. Efficacy of short-term FK506 administration on accelerating nerve regeneration. Neurorehabil Neural Repair 2012; 26: 570–580.
9. Jeng H, Dezhong L, Qiongjiao Y, Huayong Z, Shipu L. Evaluation of PRGD/FK506/NGF conduits for peripheral nerve regeneration in rats. Neurol India 2010; 58: 384–391.
10. Li X, Wang W, Wei G, Wang G, Zhang W, Ma X. Immunophenix FK506 loaded in chitosan guide promotes peripheral nerve regeneration. Biotechnol Lett 2010; 32: 1333–1337.
11. Jost SC, Doolabh VB, Mackinnon SE, Lee M, Hunter D. Acceleration of peripheral nerve regeneration following FK506 administration. Restor Neurol Neurosci 2000; 17: 39–44.
12. Chunasuwankul R, Ayruot C, Derek Z, Gal A, Lancetza M, Owen E. Low dose discontinued FK506 treatment enhances peripheral nerve regeneration. Int Surg 2002; 87: 274–278.
13. Becker DB, Jensen JN, Mykatain TM, Doolabh VB, Hunter DA, Mackinnon SE. Effects of FKBP-12 ligands following tibial nerve injury in rats. J Reconstr Microsurg 2000; 16: 613–620.
14. Haisheng H, Songjie Z, Xin L. Assessment of nerve regeneration across nerve allografts treated with tacrolimus. Antis Cells Blood Subst Immol Biotechnol 2008; 36: 465–474.
15. Chabas JF, Alluin O, Rao G, Garcia S, Lavault MN, Legre R et al. FK506 induces changes in muscle properties and promotes met abolisensitive nerve fiber regeneration. J Neurotrauma 2009; 26: 97–108.
16. Chen B, Song Y, Liu Z. Promotion of nerve regeneration in peripheral nerve by short-course FK506 after end-to-side neurosurgery. J Surg Res 2009; 152: 303–310.
17. Lagoda G, Xie Y, Szezn SF, Hurt KJ, Liu L, Musicki B et al. FK506 neuroprotection after cavernous nerve injury is mediated by thioredoxin and glutathione redox systems. J Sex Med 2011; 8: 3325–3334.
18. Li Q, Shen TG, Wu YM, Wang G. Experimental study of electrophysiologic effects of regenerative nerve fibres affected by control releasing FK506. China J Orthop Traumatol 2010; 23: 841–844.
19. Que J, Cao Q, Sui T, Du SH, Zhang AL, Kong DC et al. Tacrolimus reduces scar formation and promotes sciatic nerve regeneration. Neural Regen Res 2012; 7: 2505–2506.
20. Kuo YR, Wu WS, Jeng SF, Huang HC, Yang KD, Sacks JM et al. Activation of ERK and p38 kinase mediated keloid fibroblast apoptosis after flashlamp pulsed dye laser treatment. Lasers Surg Med 2009; 36: 31–37.
21. Sun Y, Wang L, Sun S, Liu B, Wu N, Cao. X. The effect of 10-hydroxycamptothecine in preventing fibroblast proliferation and epidermal scar adhesion after laminectomy in rats. Eur J Pharmacol 2008; 593: 44–48.
22. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239–252.
23. Jeon SH, Park HM, Kim SJ, Lee MY, Kim GB, Rahman MM et al. Taurine reduces FK506-induced generation of ROS and activation of JNK and Bax in Madin Darby canine kidney cells. Hum Exp Toxicol 2010; 29: 627–633.
24. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2001; 296: 1911–1912.
25. Dougherty CJ, Kubasik LA, Prentice H, Andreaka P, Bischosng NH, Webster KA. Activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stress. Biochim J 2002; 362: 561–571.
26. Engelbrecht AM, Nessler C, Page C, Lochner A. Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis 2010; 15: 183–195.